Castle Biosciences stock (US14843C1053): shares trade steady as Nasdaq investors eye valuation ahead of next earnings

Castle Biosciences stock traded broadly steady on the Nasdaq under the ticker CSTL this week, with investors in the United States digesting the company’s current loss-making profile and valuation ahead of the next expected earnings release, according to pricing data from Investing.com as of 05/29/2026 and consensus estimates from MarketBeat as of 05/29/2026.

The stock most recently changed hands on Nasdaq in US dollars, reflecting its primary US listing, while sector sentiment in molecular diagnostics has been shaped by expectations for continued revenue growth but ongoing operating losses, according to MarketBeat consensus data as of 05/29/2026 and peer information on Investing.com as of 05/29/2026.

For context on the company’s profitability profile, Castle Biosciences reported a trailing earnings per share (EPS) of approximately -USD 0.44 based on data compiled by MarketBeat as of 05/29/2026, highlighting that the company remains in the red on a GAAP basis while it continues to invest in commercialization and development of its diagnostic tests.

Looking ahead, MarketBeat data as of 05/29/2026 indicate that Wall Street expects the company’s annual EPS loss to narrow in the coming year, with consensus projections moving from around -USD 1.40 to roughly -USD 0.78 per share, which would still represent a loss-making profile but with an expected improvement in the depth of losses over time.

MarketBeat also notes as of 05/29/2026 that Castle Biosciences has not yet formally confirmed the exact date for its next earnings publication, but the company’s upcoming quarterly report is currently estimated for early August 2026 based on the timing of prior-year filings, giving investors a rough timeframe for the next fundamental data point from Friendswood, Texas.

Because the company is not yet profitable, conventional valuation multiples such as the price-to-earnings (P/E) ratio are not meaningful on a trailing basis, and investors on Nasdaq and on secondary trading venues in Europe instead tend to look at revenue growth, addressable market, and balance sheet strength when assessing the stock, according to data shown by Investing.com as of 05/29/2026.

As of 05/29/2026, Castle Biosciences continues to be listed on the Nasdaq in the United States with the ticker CSTL, and there is no confirmed evidence from SEC filings or Nasdaq announcements that a take-private transaction or completed delisting has occurred within the past 24 months based on public information.

For German-speaking investors who follow US-listed growth stocks, Castle Biosciences can typically be traded via off-exchange platforms such as Tradegate in euros, although liquidity and spreads may differ from the primary Nasdaq order book, according to typical cross-listing practices observed on European trading venues as of 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Castle Biosciences: core business model

Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that help physicians better assess risk and guide treatment decisions in dermatologic cancers, uveal melanoma, Barrett’s esophagus and selected mental health conditions, generating revenue primarily from test volumes ordered by clinicians and reimbursed by payers.

Valuation metrics and multiples for Castle Biosciences

On 05/29/2026, Castle Biosciences is generally viewed by the market as a growth-stage diagnostics name with negative trailing earnings, so classic valuation metrics such as the price-to-earnings ratio are not applicable in the conventional sense, as the company’s trailing EPS stands around -USD 0.44 according to MarketBeat consensus data as of 05/29/2026.

Given the negative earnings profile and an expected narrowing of losses from around -USD 1.40 to -USD 0.78 per share next year based on MarketBeat estimates as of 05/29/2026, investors tend to value Castle Biosciences using revenue multiples, gross-margin potential and addressable market sizing rather than dividend yield or EV/EBITDA, and the stock does not currently feature a regular dividend payout, aligning it more closely with other growth-oriented diagnostics peers tracked by Investing.com as of 05/29/2026.

Conclusion

Castle Biosciences shares on Nasdaq are currently trading in a relatively stable range as US investors await the company’s next expected earnings release and assess its loss-making yet improving EPS outlook indicated by MarketBeat estimates as of 05/29/2026. With negative trailing earnings and expectations for a reduced but still negative EPS over the coming year, valuation discussions center on revenue growth, addressable markets and balance sheet strength rather than traditional income-based multiples. This backdrop places Castle Biosciences firmly in the growth-oriented diagnostics segment, where execution on test adoption, reimbursement and operating leverage will be key factors for how the market values the stock over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.